Next Article in Journal
Enhanced Intestinal Permeability of Bufalin by a Novel Bufalin-Peptide-Dendrimer Inclusion through Caco-2 Cell Monolayer
Next Article in Special Issue
Design and Synthesis of Malonamide Derivatives as Antibiotics against Methicillin-Resistant Staphylococcus aureus
Previous Article in Journal
Analytical Methods of Phytochemicals from the Genus Gentiana
Previous Article in Special Issue
Synthesis and Antibacterial Activity of Benzo[4,5]isothiazolo[2,3-a]pyrazine-6,6-dioxide Derivatives
Open AccessArticle

In Vivo Activity of LCB 01-0699, a Prodrug of LCB 01-0648, against Staphylococcus aureus

1
School of Life Science, Handong Global University, Pohang 37554, Korea
2
Institute of Agricultural Science & Technology, School of Food Science and Biotechnology, Kyungpook National University, Daegu 41566, Korea
3
LegoChem BioSci. Inc., Daejeon 34302, Korea
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Molecules 2017, 22(12), 2096; https://doi.org/10.3390/molecules22122096
Received: 10 November 2017 / Revised: 23 November 2017 / Accepted: 28 November 2017 / Published: 29 November 2017
LCB01-0648 is a novel oxazolidinone compound that shows potent antibacterial activities against most Gram-positive cocci, including the multi-drug resistant Staphylococcus aureus. In this study, in vivo activity of LCB01-0699, a LCB01-0648 prodrug, against S. aureus was evaluated in comparison with that of Linezolid. The results of the systemic infection study demonstrated that LCB01-0699 was more potent than Linezolid against methicillin-susceptible and -resistant S. aureus strains. The in vivo efficacy of LCB01-0699 against methicillin-susceptible and -resistant S. aureus strains in a skin infection model showed more potent activity than Linezolid. LCB01-0699 shows potent in vivo activity against methicillin-susceptible and -resistant S. aureus strains, suggesting that LCB01-0699 would be a novel candidate for the treatment of these infectious diseases caused by S. aureus. View Full-Text
Keywords: LCB01-0699; LCB01-0648; oxazolidinone; in vivo activity; skin infection LCB01-0699; LCB01-0648; oxazolidinone; in vivo activity; skin infection
Show Figures

Figure 1

MDPI and ACS Style

Oh, S.-H.; Park, H.-S.; Lee, J.-H.; Baek, S.-Y.; Chae, S.-E.; Oh, K.; Cho, Y.L.; Kwak, J.-H. In Vivo Activity of LCB 01-0699, a Prodrug of LCB 01-0648, against Staphylococcus aureus. Molecules 2017, 22, 2096.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop